These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 19671873

  • 1. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.
    Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I.
    Clin Cancer Res; 2009 Aug 15; 15(16):5274-9. PubMed ID: 19671873
    [Abstract] [Full Text] [Related]

  • 2. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I.
    Cancer; 2014 Nov 01; 120(21):3311-9. PubMed ID: 24989332
    [Abstract] [Full Text] [Related]

  • 3. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
    Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I.
    Clin Cancer Res; 2007 Sep 01; 13(17):5144-9. PubMed ID: 17785569
    [Abstract] [Full Text] [Related]

  • 4. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
    Hassan R, Alewine C, Mian I, Spreafico A, Siu LL, Gomez-Roca C, Delord JP, Italiano A, Lassen U, Soria JC, Bahleda R, Thomas A, Steinberg SM, Peer CJ, Figg WD, Niederfellner G, Méresse Naegelen V, Pastan I.
    Cancer; 2020 Nov 15; 126(22):4936-4947. PubMed ID: 32870522
    [Abstract] [Full Text] [Related]

  • 5. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.
    Zhang J, Qiu S, Zhang Y, Merino M, Fetsch P, Avital I, Filie A, Pastan I, Hassan R.
    Anticancer Res; 2012 Dec 15; 32(12):5151-8. PubMed ID: 23225411
    [Abstract] [Full Text] [Related]

  • 6. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
    van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmbhatt H, Reid G.
    Lancet Oncol; 2017 Oct 15; 18(10):1386-1396. PubMed ID: 28870611
    [Abstract] [Full Text] [Related]

  • 7. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
    Li Q, Verschraegen CF, Mendoza J, Hassan R.
    Anticancer Res; 2004 Oct 15; 24(3a):1327-35. PubMed ID: 15274292
    [Abstract] [Full Text] [Related]

  • 8. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.
    Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J.
    Clin Cancer Res; 2007 Dec 01; 13(23):7166-71. PubMed ID: 18056197
    [Abstract] [Full Text] [Related]

  • 9. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.
    Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I.
    Mol Cancer Ther; 2013 Jan 01; 12(1):48-57. PubMed ID: 23136186
    [Abstract] [Full Text] [Related]

  • 10. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.
    Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I.
    Sci Transl Med; 2013 Oct 23; 5(208):208ra147. PubMed ID: 24154601
    [Abstract] [Full Text] [Related]

  • 11. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.
    Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D.
    Clin Cancer Res; 2010 Dec 15; 16(24):6132-8. PubMed ID: 21037025
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
    Sewak S, Sorich J, O'Leary J.
    Anticancer Drugs; 2006 Jun 15; 17(5):571-9. PubMed ID: 16702815
    [Abstract] [Full Text] [Related]

  • 13. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
    Calabrò L, Morra A, Giannarelli D, Amato G, D'Incecco A, Covre A, Lewis A, Rebelatto MC, Danielli R, Altomonte M, Di Giacomo AM, Maio M.
    Lancet Respir Med; 2018 Jun 15; 6(6):451-460. PubMed ID: 29773326
    [Abstract] [Full Text] [Related]

  • 14. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Nowak AK, Lesterhuis WJ, Kok PS, Brown C, Hughes BG, Karikios DJ, John T, Kao SC, Leslie C, Cook AM, Pavlakis N, Briscoe K, O'Byrne KJ, Karapetis CS, Lam WS, Langford A, Yip S, Stockler MR.
    Lancet Oncol; 2020 Sep 15; 21(9):1213-1223. PubMed ID: 32888453
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
    Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen FL, Delord JP, Dowlati A, Kochuparambil ST, Taylor MH, Powderly JD, Vaishampayan UN, Verschraegen C, Grote HJ, von Heydebreck A, Chin K, Gulley JL.
    JAMA Oncol; 2019 Mar 01; 5(3):351-357. PubMed ID: 30605211
    [Abstract] [Full Text] [Related]

  • 16. Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.
    Takeda M, Ohe Y, Horinouchi H, Hida T, Shimizu J, Seto T, Nosaki K, Kishimoto T, Miyashita I, Yamada M, Kaneko Y, Morimoto C, Nakagawa K.
    Lung Cancer; 2019 Nov 01; 137():64-70. PubMed ID: 31557561
    [Abstract] [Full Text] [Related]

  • 17. Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.
    Mazor R, Zhang J, Xiang L, Addissie S, Awuah P, Beers R, Hassan R, Pastan I.
    Mol Cancer Ther; 2015 Dec 01; 14(12):2789-96. PubMed ID: 26443804
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
    Hassan R, Schweizer C, Lu KF, Schuler B, Remaley AT, Weil SC, Pastan I.
    Lung Cancer; 2010 Jun 01; 68(3):455-9. PubMed ID: 19744744
    [Abstract] [Full Text] [Related]

  • 19. Mesothelin targeted cancer immunotherapy.
    Hassan R, Ho M.
    Eur J Cancer; 2008 Jan 01; 44(1):46-53. PubMed ID: 17945478
    [Abstract] [Full Text] [Related]

  • 20. Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts.
    Hassan R, Williams-Gould J, Steinberg SM, Liewehr DJ, Yokokawa J, Tsang KY, Surawski RJ, Scott T, Camphausen K.
    Clin Cancer Res; 2006 Aug 15; 12(16):4983-8. PubMed ID: 16914588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.